drugset
drugset / Trial / NCT00281021

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

NCT00281021 ↗

Phase 2 Terminated 26 enrolled University of Louisville James Graham Brown Cancer Center · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.

Timeline

Start
2006-02
Primary completion
2010-12
Completion
2010-12

Outcome

Outcome not reported

Stopped: “Interim analysis revealed that only 1 patient had a partial response.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified — —
Subject Erlotinib Small molecule — —

Indications

non-small cell lung carcinoma